Business
InvestmentPitch Media Video Discusses Voyageur Pharmaceuticals' Two New License Approvals from Health Canada for its MultiX Barium Sulfate Powder Covering Oral and Rectal Applications - Video Available on Investmentpitch.com
Vancouver, British Columbia--(Newsfile Corp. - April 7, 2021) -  Voyageur Pharmaceuticals...
About this update from Voyageur Pharmaceuticals Ltd
[{"type":"text","content":"InvestmentPitch Media Video Discusses Voyageur Pharmaceuticals' Two New License Approvals from Health Canada for its MultiX Barium Sulfate Powder Covering Oral and Rectal Applications - Video Available on Investmentpitch.comVancouver, British Columbia--(Newsfile Corp. - April 7, 2021) -  Voyageur Pharmaceuticals (TSXV: VM) (OTC: VYYRF) has received two license approvals from Health Canada for its MultiX barium sulfate powder. The two licenses cover both oral and rectal applications. MultiX is specifically designed for oral suspension and indicated for use in single contrast radiographic examinations of the esophagus, stomach, duodenum and small bowel to visualize the gastrointestinal tract in adult and pediatric patients.MultiX, along with the recent approval for SmoothX, the company's barium radiographic contrast suspension specifically formulated for CT Scans, and HDX Ba, (HDX barium) a barium radiographic contrast powder specifically formulated for Fluoroscopy barium X-Ray procedures, gives the company 3 Health Canada approved and licensed drugs, with 2 more in the offing.For more information, please view the InvestmentPitch Media \"video\" which provides additional information about this news and the company. If this link is not enabled, please visit www.InvestmentPitch.com and enter \"Voyageur\" in the search box.Cannot view this video? Visit:https://www.youtube.com/watch?v=1LhUNnMfwAAContrast materials, which may be taken orally or rectally, are used to improve pictures of the inside of the body helping to distinguish or \"contrast\" selected areas of the body from surrounding tissue allowing the radiologist to distinguish normal from abnormal conditions.At the time of the recent Health Canada approvals for SmoothX and HDX Ba, Brent Willis, President and CEO, had stated: \"Voyageur's business plan has always been to launch Barium Contrast Radiographic Suspension products into the Canadian marketplace initially, then pursue other markets. This approval is the critical milestone to allow our company to transition to a cash flowing pharmaceutical company.\"Voyageur is building a suite of barium radiographic contrast media products and is working with its custom manufacturer, Alberta Veterinarian Laboratories (\"AVL\"), which owns and operates a brand new, multi-million dollar, state-of-the-art, Good Manufacturing Practic...